Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 1017-1022

  Watanuki, Akira ^a   Ohwada, Susumu ^a   Fukusato, Toshio ^b   Kawate, Susumu ^a   Makita, Fujio ^c   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c Shibukawa Medical Center   (Japan)

Author keywords

Anti HCV antibody; Argyrophilic nucleolar organizer regions; C myc; Hepatocellular carcinoma; Ki 67; MIB 1; P53; Proliferative acitivity

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME NOR; CLINICAL FEATURE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SILVER STAINING; TUMOR GROWTH;

EID: 0031792513     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.1017     Document Type: Article

References (39)

1. Nishioka K, Watanabc J, Furuta S, Tanaka E, lino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo Q, Houghton M and Oda T: A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67: 429-433, 1991.
2. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Watanabe G and Tsurumaru M: Risk factor of tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 71: 19-25, 1993.
3. Haratake J, Takeda S, Kasai T, Nakano S and Tokui N: Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer 72: 1178-1183, 1993.
4. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, Ogura K, Niwa Y, Kawabe T and Omata M: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 22: 1027-1033, 1995.
5. Tanizaki H, Ryu M, Kinoshita T, Kawano N, Konishi M, Cho A, Nakatsura T, Natsume T, Takahashi S, Sugita M, Izuishi K, Yoshino M, Furuse J, Iwasaki M and Tsubono Y: Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn J Clin Oncol 27: 67-70, 1997.
6. Miyagawa S, Kawasaki S and Makuuchi M: Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 24: 307-310, 1996.
7. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A and Miyazaki I: Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106: 720-727, 1994.
8. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N and Morioka Y: Postoperative recurrence of hepato-cellular carcinoma. Ann Surg211:28-33, 1990.
9. Nagashima I, Hamada C, Naruse K, Osada T, Nagao T, Kawano N and Muto T: Surgical resection for small hepatocellular carcinoma. Surgery 119: 40-45, 1996.
10. Shimizu K, Izumi R, Ii T, Muraoka K, Inoue T, Fukushima W, Sakamoto K, Tani T, Hashimoto T, Yagi M, Miyazaki I and Nonomura A: Prognostic significance of nucleolar organizer regions in hepatocellular carcinoma. Hepatology 21: 393-397, 1995.
11. Nonomura A, Mizukami Y, Matsubara F and Nakanuma Y: Identification of nucleolar organizer regions in non-neoplastic and neoplastic hepatocytes by the silver-staining technique. Liver 10: 229-238, 1990.
12. Ng IO, Na J, Lai EC, Fan ST and Ng M: Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB-1. Am J Clin Pathol 104:313-318, 1995.
13. Yoshimoto J, Iwata T, Takamori S, Kojima K and Futagawa S: Usefulness of monoclonal antibody Ki-67 as a prognostic factor of hepatocellular carcinoma. Int Hepatol Commun 6: 209-218, 1997.
14. Adachi E, Hashimoto H and Tsuneyoshi M: Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer 72: 479-486, 1993.
15. Ng IO, Lai EC, Fan S, Ng M, Chan AS and So MK: Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 73: 2268-2274, 1994.
16. Abon Elella A, Gramlich T, Fritsh C and Gransler T: c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 9: 95-98, 1996.
17. Kawate S, Fukusato T, Ohwada S, Watanuki A and Morishita Y: Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity, and p53 overexpression. Oncology (In press).
18. Nagao T, Kondo F, Sato T, Nagato Y and Kondo Y: Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma: correlation with cell proliferative activity indices, including mitotic index and MIB-1 immunostaining. Hum Pathol 26: 326-333, 1995.
19. D'Errico A, Grigioni W, Fiorentino M, Baccarini P, Grazi GL and Mancint AM: Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int 44: 682-687, 1994.
20. Saegusa M, Takano Y, Kishimoto H, Wakabayashi G, Nohga K and Okudaira M: Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinoma- an enhanced immunohistochemical approach. J Cancer Res Clin Oncol 119: 737-744, 1993.
21. Crocker J and Nar P: Nucleolar organizer regions in lymphomas. J Pathol 151: 111-118, 1987.
22. Crocker J, Boludy DAR and Egan MJ: How should we count AgNORs? Proposals for a standardized approach. J Pathol 158: 185-188, 1989.
23. Howat AJ, Giri DD, Wright AL and Underwood JCE: Silverstained nucleoli and nucleolar organizer region counts are of no prognostic value in thick cutaneous malignant melanoma. J Pathol 156:227-232, 1988.
24. Frye RA, Benz CC and Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4: 1153-1157, 1989.
25. Underwood MA, Barlett JMS and Cooke TG: An improved method for semiquantification of gene amplification from archival material. PCR Meth Appl 4: 178-184, 1994.
26. Gotoh M, Nakajima T, Yokota J, Tsunokawa Y, Terada M, Shimoyama Y, Teshima S, Hirohashi S and Shimosato Y: Newly established uterine cervical carcinoma cell line with coamplification of human papillomavirus DNA and c-myc gene. Jpn J Cancer Res 82: 1252-1257, 1991.
27. Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 7: 462-503, 1954.
28. Brechot C, Hadchouel M, Scotto J, Degos F, Charnay P, Trepo C and Tiollais P: Detection of hepatitis B virus DNA in liver and serum: a detect appraisal of the chronic carrier state. Lancet 8250: 765-768, 1981.
29. Takano S, Yokosuka O, Imazeki F, Tagawa M and Omata M: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21: 650-655, 1995.
30. Chisari F, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL and Palmiter RD: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-1156, 1989.
31. Farinati F, Cardin R, D'Errico A, Maria ND, Naccarato R, Cecchetto A and Grigioni W: Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB-1 Ki67 in archival material: the role of etiology, disease activity, iron, and lipid peroxidation. Hepatology 23: 1468-1475, 1996.
32. Gonzalez-Peralta RP, Davis GL and Lau JYN: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 21: 255-259, 1994.
33. Key G, Becker MHG, Baron B, Duchrow M, Schlüter C, Flad H and Gerdes J: New Ki-67-eqivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed part of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68: 629-636, 1993.
34. Stahl A: The nucleolus and nucleolar chromosomes: In: The Nucleolus. Jordon EG and Cullis CA (eds). Cambridge University Press, London, pp1-24, 1982.
35. Derenzini M, Pession A and Trere D: Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab Invest 63: 137-140, 1990.
36. Garte ST: The c-myc oncogene in tumor progression. Crit Rev Oncog 4: 435-449, 1993.
37. Trowbridge R, Fagan EA, Davison F, Eddleston ALWF, Williams R, Linskens MHK and Farzaneh F: Amplification of the c-myc gene locus in a human hepatic tumor containing integrated hepatitis B virus DNA. In: Viral Hepatitis and Liver Disease. Zeckerman AJ (ed). Alan R Liss, New York, pp764-768, 1987.
38. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K and Sugimachi K: The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 22: 1702-1707, 1995.
39. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K and Maeda S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54: 231-235, 1994.